Search: onr:"swepub:oai:prod.swepub.kib.ki.se:146496856" >
Second allogeneic t...
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
-
Hayden, PJ (author)
-
Eikema, DJ (author)
-
de Wreede, LC (author)
-
show more...
-
Koster, L (author)
-
Kroger, N (author)
-
Einsele, H (author)
-
Minnema, M (author)
-
Dominietto, A (author)
-
Potter, M (author)
-
Passweg, J (author)
-
Bermudez, A (author)
-
Nguyen-quoc, S (author)
-
Platzbecker, U (author)
-
Tischer, J (author)
-
Ciceri, F (author)
-
Veelken, JH (author)
-
- Ljungman, P (author)
- Karolinska Institutet
-
Schaap, N (author)
-
Forcade, E (author)
-
Carella, AM (author)
-
Gandemer, V (author)
-
Arcese, W (author)
-
Bloor, A (author)
-
Olivieri, A (author)
-
Vincent, L (author)
-
Beksac, M (author)
-
Schonland, S (author)
-
Yakoub-Agha, I (author)
-
show less...
-
(creator_code:org_t)
- 2021-05-11
- 2021
- English.
-
In: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 56:10, s. 2367-2381
- Related links:
-
https://www.nature.c...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24–46%); Others 9% (0–17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33–67%); Other 22% (8–36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21–40%) vs. 10% (1–20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24–0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hayden, PJ
-
Eikema, DJ
-
de Wreede, LC
-
Koster, L
-
Kroger, N
-
Einsele, H
-
show more...
-
Minnema, M
-
Dominietto, A
-
Potter, M
-
Passweg, J
-
Bermudez, A
-
Nguyen-quoc, S
-
Platzbecker, U
-
Tischer, J
-
Ciceri, F
-
Veelken, JH
-
Ljungman, P
-
Schaap, N
-
Forcade, E
-
Carella, AM
-
Gandemer, V
-
Arcese, W
-
Bloor, A
-
Olivieri, A
-
Vincent, L
-
Beksac, M
-
Schonland, S
-
Yakoub-Agha, I
-
show less...
- Articles in the publication
-
Bone marrow tran ...
- By the university
-
Karolinska Institutet